ClinicalTrials.gg
CompletedNCT02676089TRIGGERUpdated Jun 26, 2026Results posted

TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)

A Phase 3 interventional study of CHF 5993 200/6/12.5 µg and CHF 1535 200/6 µg in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 244 sites in 17 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,437
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..

Enrollment
2nd of 66
1,437 · median 97
Started
2016
with 3 others
Phase 3
24 of 81
2 open now
Registered
44th of 81
by date

Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 2nd largest by enrollment of the 66 interventional ones that give a count, is one of 4 that started in 2016, is one of 24 in phase 3, and was the 44th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Asthma by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

Evaluate the superiority of CHF 5993 200/6/12.5 µg pressurised metered dose inhaler (pMDI) (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) versus CHF 1535 200/6 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate) in patients with uncontrolled asthma under medium doses of inhaled corticosteroid/long-acting β2-adrenergic receptor agonists (ICS/LABA), in patients with uncontrolled asthma who received medium doses of ICS/LABA.

The treatments tested the improvement of the forced expiratory volume in the 1st second (FEV1) and the reduction of moderate and severe asthma exacerbations rate.

Read the detailed description

This was a phase III, multicentre, randomised, double-blind study, with an open-label arm, active-controlled, 3-arm parallel group study to demonstrate both the superiority of CHF 5993 pMDI 200/6/12.5 μg compared with CHF 1535 pMDI 200/6 μg in terms of change from baseline in pre-dose FEV1 at Week 26 and a reduction of moderate and severe asthma exacerbation rate with CHF 5993 pMDI 200/6/12.5 μg compared to CHF 1535 pMDI 200/6 μg during the entire 52-week treatment period.

The study was performed in patients with uncontrolled asthma on high doses of inhaled corticosteroids (ICS) in combination with long acting β2-agonists LABAs). The study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines and all other requirements of local laws.

Patients completed the electronic diary (eDiary)/electronic peak flow meter (ePeakflowmeter) twice daily at home from screening to Week 52, recording asthma symptoms, treatment compliance, rescue intake and peak expiratory flow (PEF). The Asthma Control Questionnaire© (ACQ)-7 was completed at all visits from screening to Week 52. The EuroQuality of Life-5-Dimensional-3-Level (EQ-5D-3L™) questionnaire was completed at all visits from randomisation to Week 52. Health economic information was collected during the study. An independent Data Safety Monitoring Board was established for evaluation of the study and impartial safety assurance for patients. An Adjudication Committee was established to evaluate Major Adverse Cardiovascular Events.

Primary objective of the study were:

  • To demonstrate the superiority of CHF 5993 pMDI 200/6/12.5 μg compared with CHF 1535 pMDI 200/6 μg in terms of change from baseline in pre-dose forced expiratory volume in the 1st second (FEV1) at Week 26;
  • To demonstrate the reduction of moderate and severe asthma exacerbations rate with CHF 5993 pMDI 200/6/12.5 μg compared with CHF 1535 pMDI 200/6 μg during the entire 52-week treatment period.

The secondary endpoints included pooled analyse of 2 pivotal studies; this study (TRIGGER) and study (TRIMARAN). These 2 studies have similar study designs and study population.

CHF 1535 pMDI: fixed-dose combination (FDC) of BDP + FF + GB Dose: BDP 200 μg, FF 6 μg, GB 12.5 μg per actuation, 2 inhalations, BID. Total daily dose: BDP 800 μg, FF 24 μg, GB 50 μg.

BDP: Beclometasone dipropionate FF: Formoterol fumarate GB: Glycopyrronium bromide

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma, Anticholinergics, Triple combination
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of asthma ≥ 1 year and diagnosed before 40 years old
  • Uncontrolled asthma with double therapy only on high doses of Inhaled (ICS) in combination with Long-Acting Beta2 Agonist (LABA) with ACQ-7 (Asthma Control Questionnaire) ≥1.5
  • Pre-bronchodilator \<80% of the predicted normal value
  • Positive reversibility test
  • At least 1 documented asthma exacerbation in the previous year

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women
  • Diagnosis of (COPD)
  • Patients with any asthma exacerbation or respiratory tract infection in the 4 weeks prior screening
  • Current smoker or ex-smoker (>= 10 packs year)
  • Any change in dose, schedule or formulation of ICS + LABA combination in the 4 weeks prior screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,437 participants (actual)

Study arms

  • Experimental
    CHF 5993 200/6/12.5 µg

    Treatment A: CHF 5993 200/6/12.5 µg: 2 inhalations bid Total daily dose: 800/24/50 µg BDP/FF/GB

    Drug: CHF 5993 200/6/12.5 µg

  • Active comparator
    CHF 1535 200/6 µg

    Treatment B: CHF 1535 200/6 µg: 2 inhalations bid Total daily dose: 800/24 µg BDP/FF

    Drug: CHF 1535 200/6 µg

  • Active comparator
    CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg

    Treatment C (open-label arm): CHF 1535 200/6 µg: 2 inhalations bid \+ Tiotropium Respimat 2.5 µg: 2 inhalations od Total daily dose: 800/24 µg BDP/FF + 5 µg Tio

    Drug: CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg

Interventions

  • DrugCHF 5993 200/6/12.5 µg
  • DrugCHF 1535 200/6 µg
  • DrugCHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
06

What researchers measure

Primary outcomes

  1. 1_Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Week 26

    Change from baseline in pre-dose FEV1, analysed at Week 26 of treatment. FEV1=Forced expiratory volume in the first second

    Time frame: Week 0 (pre-treatment, baseline) to Week 26.

  2. 2_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period

    Asthma exacerbation intensity: Moderate AND Severe Asthma Exacerbation Severe: asthma worsening requiring initiation of treatment with systemic corticosteroids for at least 3 days (courses of corticosteroids separated by ≥1 week treated as separate severe exacerbations). Moderate: ≥1 of the following criteria fulfilled and leading to a change in treatment (sustained increase of ≥1 puff of short acting beta 2-agonist \[SABA\] for 2 consecutive days) as shown below: * Nocturnal awakening(s) due to asthma requiring SABA for 2 consecutive nights/increase of ≥ 0.75 from baseline in daily symptom score on 2 consecutive days; increase from baseline in occasions of SABA use on 2 consecutive days (minimum increase 4 puffs/day); * ≥20% decrease in peak expiratory flow from baseline on at least 2 consecutive mornings/evenings or ≥ 20% decrease in FEV1 from baseline; * Visit to the ER/trial site for asthma treatment not requiring systemic corticosteroid;

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

Secondary outcomes

  1. 3_Change From Baseline in Peak(0-3h) FEV1 at Week 26

    Peak peak of forced expiratory volume in the first second (FEV1) within 3 hours post-dose. FEV1=Forced expiratory volume in the first second

    Time frame: Week 0 (pre-treatment, baseline) and Week 26.

  2. 4_Change From Baseline in Morning Peak Expiratory Flow (PEF) Over the 26-Week Treatment

    Change from baseline in the average morning PEF (Litre/min), measured by patients at home over the 26-week treatment period (i.e., up to Week 26). PEF=Peak Expiratory Flow; is the maximal airflow forcefully expelled from the lungs in one quick exhalation.

    Time frame: Week 0 (pre-treatment, baseline) to Week 26.

  3. 5_Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period - Pooled Analysis

    Severe asthma exacerbation rate over the 52-Week treatment period in a pre-specified pooled analysis of 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

    Time frame: The entire treatment period; up to Week 52.

  4. 6_Change From Baseline in Peak FEV1 (0-3h) at All Clinical Visits

    The peak (0-3h) FEV1 at baseline and at all subsequent visits, and the respective changes from baseline are presented by treatment group for all clinical visits. Baseline for pre-dose FEV1 was calculated as average of the FEV1 measurements (L) from the visit 2 (V2) Pre45min \& V2 Pre15min. If one of the two pre-dose values was missing, the baseline was equal to the available pre-dose value. FEV1=Forced expiratory volume in the first second

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  5. 7_Change From Baseline in Pre-Dose FEV1 at All Clinical Visits

    Results show the change from baseline in pre-dose FEV1 at all clinical visits. FEV1=Forced expiratory volume in the first second

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  6. 8_FEV1 Response (FEV1 ≥ 100 mL) at Week 26 and Week 52

    Results show the percentage of patients classified as FEV1 responders at Week 26 and at Week 52. The FEV1 response was defined as: Change from baseline in pre-dose morning FEV1 ≥ 100 mL. FEV1=Forced expiratory volume in the first second

    Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.

  7. 9_Change From Baseline in FEV1 Area Under the Curve (AUC) (0-3h) Normalised by Time at All Clinical Visits

    Baseline definition: mean of two pre-dose FEV1 measurements at visit 2 (V2). Results show the change from baseline in FEV1 area under the curve \[AUC\] (0-3h) at all subsequent visits (i.e. change from baseline of the AUC of the serial post-dose spirometry assessments till 3h post-dose). FEV1=Forced expiratory volume in the first second

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  8. 10_Change From Baseline in the Asthma Control Questionnaire-7 (ACQ-7) Score at All Clinical Visits

    ACQ-7 Questionnaire. ACQ-7 allows assessment of asthma control in individual patients. The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue medication use and 1 on lung function (FEV1 % predicted). All seven items are scored on a 7-point Likert scale, with 0 indicating total control (no impairment) and 6 indicating poor control (maximum impairment). The questions are equally weighted and the total score is the mean of the seven items. The first 6 questions of the ACQ-7 were completed by the participant while the last question was completed by the study investigator using data from the Master Scope spirometer. Baseline for ACQ-7 was the total score recorded at Visit 2 (Week 0) of the study. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. A negative change from baseline indicates improvement in lung function.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  9. 11_Asthma Control Questionnaire©-7 Response at Week 26 and Week 52

    Asthma Control Questionnaire (ACQ) and Asthma Control Questionnaire-7 (QAC-7) are defined in the description of Outcome measure 10 above. An ACQ-7 response was defined as change from baseline (Week 0, pre-dose) in ACQ-7 score ≤ -0.5; non-response was defined as change from baseline in ACQ-7 score \>-0.5 or missing data. Results represent responders (i.e. change from baseline in ACQ-7 Score ≤ -0.5) at Week 26 and at Week 52.

    Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.

  10. 12_Change From Baseline in Average Morning PEF (L/Min) Over 52 Weeks of Treatment

    Change from baseline in average MORNING PEF (L/min) over 52 weeks of treatment. PEF=Peak Expiratory Flow; is the maximal airflow forcefully expelled from the lungs in one quick exhalation.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  11. 12a_Change From Baseline in Average Evening PEF (L/Min) Over 26 and 52 Weeks of Treatment

    Change from baseline in average EVENING PEF (L/min) over 26 and 52 weeks of treatment. PEF=Peak Expiratory Flow; is the maximal airflow forcefully expelled from the lungs in one quick exhalation.

    Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.

  12. 13_Number of Patients at Risk of Moderate or Severe Asthma Exacerbation Over 52 Weeks

    Number of patients at risk of a moderate or severe asthma exacerbation. Results show the number of patients who had moderate or severe asthma exacerbation over the 52 weeks treatment period.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  13. 14_Number of Patients at Risk of Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02

    Number of patients at risk of a SEVERE asthma exacerbation in the pooled analysis of the two pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER), over the 52 weeks treatment period. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

    Time frame: Week 0 (Baseline) to 52 weeks for both studies in the pooled analysis.

  14. 15_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02.

    MODERATE asthma exacerbation rate over the 52-Week treatment period in the pooled analysis of the 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-055993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

    Time frame: Week 0 (Baseline) to 52 weeks for both studies in the pooled analysis.

  15. 16_Number of Patients at Risk of MODERATE Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02

    Number of Patients at Risk of MODERATE Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

    Time frame: Week 0 (Baseline) to 52 weeks for both studies in the pooled analysis.

  16. 17_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02

    Moderate AND severe asthma exacerbation rate over the 52-Week treatment period in the pooled analysis of the 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

    Time frame: Week 0 (Baseline) to 52 weeks for both studies in the pooled analysis.

  17. 18_Number of Patients at Risk of Moderate OR Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02

    Time to first MODERATE OR SEVERE asthma exacerbation in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

    Time frame: Week 0 (Baseline) to 52 weeks for both studies in the pooled analysis.

  18. 19_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period

    MODERATE asthma exacerbation rate over the 52-Week treatment period. Asthma exacerbation intensity: Moderate: ≥1 of the following criteria fulfilled and leading to a change in treatment (sustained increase of ≥1 puff of short acting beta 2-agonist \[SABA\] for 2 consecutive days) as shown below: * Nocturnal awakening(s) due to asthma requiring SABA for 2 consecutive nights/increase of ≥ 0.75 from baseline in daily symptom score on 2 consecutive days; increase from baseline in occasions of SABA use on 2 consecutive days (minimum increase 4 puffs/day); * ≥20% decrease in peak expiratory flow from baseline on at least 2 consecutive mornings/evenings or ≥ 20% decrease in FEV1 from baseline; * Visit to the ER/trial site for asthma treatment not requiring systemic corticosteroid;

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  19. 20_Number of Patients at Risk of a MODERATE Asthma Exacerbation

    Data were analysed for the number of patients at risk of a MODERATE asthma exacerbation.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  20. 21_Change From Baseline in the Average Use of Rescue Medication Over the 26- and 52-Week Treatment Periods

    Change from baseline in the average use of rescue medication over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study.

    Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.

  21. 21a_Change From Baseline in the Average Use of Rescue Medication in Each Inter-Visit Period

    Results show the change from baseline in the average use (puffs/day) of rescue medication in each inter-visit period. Data was collected through an electronic daily diary from screening to the end of the study.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  22. 22_Change From Baseline in the Percentage of Rescue Medication-Free Days Over the 26- and 52-Week Treatment Periods

    Change from baseline in the percentage of rescue medication-free days over the 26- and 52-Week treatment periods. Data was collected using an electronic daily diary, from screening to the end of the study.

    Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.

  23. 22a_Change From Baseline in the Percentage of Rescue Medication-Free Days in Each Inter-Visit Period Over the Treatment

    Results show the change from baseline in the percentage of rescue medication-free days in each inter-visit period over the entire treatment. Data was collected through an electronic daily diary from screening to the end of the study.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  24. 23_Change From Baseline in the Average Total Daily Asthma Symptom Scores Over the 26- and 52-Week Treatment Periods

    Results show the change from baseline in the average total daily asthma symptom scores over the 26- and 52-Weeks of treatment. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered: cough, wheeze, chest tightness, breathlessness. Morning (night-time asthma symptom score): * 0 No symptoms; * 1 Mild = Symptoms not causing awakening; * 2 Moderate = Discomfort enough to cause awakenings; * 3 Severe = Causing awakenings for most of the night/did not sleep at all. Evening (daytime asthma symptom score): * 0 No symptoms; * 1 Mild = Aware of symptoms, which could be easily tolerated; * 2 Moderate = Discomfort enough to cause interference with daily activity; * 3 Severe = Incapacitating

    Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.

  25. 23a_Change From Baseline in the Average Daily Asthma Symptom Scores in Each Inter-Visit Period

    Results show the change from baseline in the average total daily asthma symptom scores over the 26- and 52-Weeks of treatment. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered: cough, wheeze, chest tightness, breathlessness. Morning (night-time asthma symptom score): * 0 No symptoms; * 1 Mild = Symptoms not causing awakening; * 2 Moderate = Discomfort enough to cause awakenings; * 3 Severe = Causing awakenings for most of the night/did not sleep at all. Evening (daytime asthma symptom score): * 0 No symptoms; * 1 Mild = Aware of symptoms, which could be easily tolerated; * 2 Moderate = Discomfort enough to cause interference with daily activity; * 3 Severe = Incapacitating

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  26. 24_Change From Baseline in the Percentage of Asthma Symptom-Free Days Over the 26- and 52-Week Treatment Periods

    Change from baseline in the percentage of asthma symptom-free days over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study. Results show the change from baseline in the average daily asthma symptom scores over the 26- and 52-Week treatment periods. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered by the questionnaire: cough, wheeze, chest tightness, breathlessness. An asthma symptom-free day is a day with total daily asthma symptom score = 0. For a description of the score see outcome measure number 23.

    Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.

  27. 24a_Change From Baseline in the Percentage of Asthma Symptom-Free Days in Each Inter-Visit Periods

    Results show the change from baseline in the percentage of asthma symptom-free days in each inter-visit periods over the entire treatment. Data was collected through an electronic daily diary from screening to end of the study. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered by the questionnaire: cough, wheeze, chest tightness, breathlessness. An asthma symptom-free day is a day with total daily asthma symptom score = 0. For a description of the score see outcome measure number 23.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  28. 25_Change From Baseline in the Percentage of Asthma Control Days Over the 26- and 52-Week Treatment Periods

    Results show the change from baseline in the percentage of asthma control days over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study. Scoring of asthma symptoms (overall symptoms, cough, wheeze, chest tightness and breathlessness): Morning (night-time asthma symptoms): 0 (no symptoms), 1 (mild - symptoms not causing awakening), 2 (moderate - discomfort enough to cause awakenings) and 3 (severe - causing awakenings for most of the night/did not sleep at all). Evening (daytime asthma symptoms): 0 (no symptoms), 1 (mild: aware of symptoms that could be easily tolerated), 2 (moderate: discomfort enough to cause interference with daily activity), 3 (severe: incapacitating with inability to work/take part in usual activity).

    Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.

  29. 25a_Change From Baseline in the Percentage of Asthma Control Days in Each Inter-Visit Period

    A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Data was collected through an electronic daily diary from screening to the end of the study. Scoring of asthma symptoms (overall symptoms, cough, wheeze, chest tightness and breathlessness): Morning (night-time asthma symptoms): 0 (no symptoms), 1 (mild - symptoms not causing awakening), 2 (moderate - discomfort enough to cause awakenings) and 3 (severe - causing awakenings for most of the night/did not sleep at all). Evening (daytime asthma symptoms): 0 (no symptoms), 1 (mild: aware of symptoms that could be easily tolerated), 2 (moderate: discomfort enough to cause interference with daily activity), 3 (severe: incapacitating with inability to work/ take part in usual activity).

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

07

Results

Posted May 29, 2026

Participant flow

Overall, 2100 patients were screened according to inclusion and exclusion criteria; of these,1437 patients were randomised. Overall, 6 patients were randomised in error and did not start treatment (N=2 in the CHF 5993 pMDI 200/6/12.5 μg group, N=3 in the CHF 1535 pMDI 200/6 μg group, and N=1 in CHF 1535 pMDI 200/6 μg + tiotropium 2.5 µg group ). The data set Safety population used for the evaluations represents 1431 patients.

Participant flow — Overall Study
MilestoneCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg
Started573576288
Completed534533262
Not completed394326
Withdrew: Withdrawal by subject262520
Withdrew: Adverse event372
Withdrew: Adverse event - serious, fatal110
Withdrew: Patient decision010
Withdrew: Patient moved to another town100
Withdrew: Safety concern001
Withdrew: Unblinding code broken100
Withdrew: Lost to follow-up011
Withdrew: Pregnancy201
Withdrew: Lack of efficacy200
Withdrew: Protocol violation381

Outcome measures

Primary1_Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Week 26

Change from baseline in pre-dose FEV1, analysed at Week 26 of treatment. FEV1=Forced expiratory volume in the first second

Time frame:
Week 0 (pre-treatment, baseline) to Week 26.
Reported as:
Least squares mean · Liter
1_Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Week 26
LiterCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg
1_Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Week 260.229 (0.196 to 0.263)0.157 (0.123 to 0.190)0.274 (0.227 to 0.321)
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.003 · Least square mean difference: 0.073 · 95% CI 0.026 to 0.120
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.125 · Least square mean difference: -0.045 · 95% CI -0.103 to 0.013
Primary2_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period

Asthma exacerbation intensity: Moderate AND Severe Asthma Exacerbation Severe: asthma worsening requiring initiation of treatment with systemic corticosteroids for at least 3 days (courses of corticosteroids separated by ≥1 week treated as separate severe exacerbations). Moderate: ≥1 of the following criteria fulfilled and leading to a change in treatment (sustained increase of ≥1 puff of short acting beta 2-agonist \[SABA\] for 2 consecutive days) as shown below: * Nocturnal awakening(s) due to asthma requiring SABA for 2 consecutive nights/increase of ≥ 0.75 from baseline in daily symptom score on 2 consecutive days; increase from baseline in occasions of SABA use on 2 consecutive days (minimum increase 4 puffs/day); * ≥20% decrease in peak expiratory flow from baseline on at least 2 consecutive mornings/evenings or ≥ 20% decrease in FEV1 from baseline; * Visit to the ER/trial site for asthma treatment not requiring systemic corticosteroid;

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Least squares mean · events/year
2_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period
events/yearCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
2_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period1.726 (1.543 to 1.932)1.963 (1.757 to 2.192)1.613 (1.373 to 1.897)
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Negative binomial model · p = 0.110 · Adjusted rate ratio: 0.880 · 95% CI 0.751 to 1.030
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Negative binomial model · p = 0.502 · Adjusted rate ratio: 1.070 · 95% CI 0.878 to 1.303
Secondary3_Change From Baseline in Peak(0-3h) FEV1 at Week 26

Peak peak of forced expiratory volume in the first second (FEV1) within 3 hours post-dose. FEV1=Forced expiratory volume in the first second

Time frame:
Week 0 (pre-treatment, baseline) and Week 26.
Reported as:
Least squares mean · Liter
3_Change From Baseline in Peak(0-3h) FEV1 at Week 26
LiterCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg
3_Change From Baseline in Peak(0-3h) FEV1 at Week 260.522 (0.488 to 0.556)0.417 (0.383 to 0.451)0.555 (0.507 to 0.603)
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.105 · 95% CI 0.057 to 0.153
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.271 · Adjusted mean difference: -0.033 · 95% CI -0.092 to 0.026
Secondary4_Change From Baseline in Morning Peak Expiratory Flow (PEF) Over the 26-Week Treatment

Change from baseline in the average morning PEF (Litre/min), measured by patients at home over the 26-week treatment period (i.e., up to Week 26). PEF=Peak Expiratory Flow; is the maximal airflow forcefully expelled from the lungs in one quick exhalation.

Time frame:
Week 0 (pre-treatment, baseline) to Week 26.
Reported as:
Least squares mean · Liter/min
4_Change From Baseline in Morning Peak Expiratory Flow (PEF) Over the 26-Week Treatment
Liter/minCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
4_Change From Baseline in Morning Peak Expiratory Flow (PEF) Over the 26-Week Treatment10.102 (6.717 to 13.487)2.297 (-1.091 to 5.684)10.286 (5.540 to 15.032)
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.001 · Adjusted mean difference: 7.805 · 95% CI 3.016 to 12.594
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.951 · Adjusted mean difference: -0.184 · 95% CI -6.013 to 5.645
Secondary5_Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period - Pooled Analysis

Severe asthma exacerbation rate over the 52-Week treatment period in a pre-specified pooled analysis of 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

Time frame:
The entire treatment period; up to Week 52.
Reported as:
Least squares mean · events/year
5_Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period - Pooled Analysis
events/yearCHF 5993 200/6/12.5 µgCHF 1535 200/6 µg
5_Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period - Pooled Analysis0.239 (0.206 to 0.276)0.310 (0.271 to 0.354)
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Negative binomial model · p = 0.008 · Adjusted rate ratio: 0.770 · 95% CI 0.636 to 0.933
Secondary6_Change From Baseline in Peak FEV1 (0-3h) at All Clinical Visits

The peak (0-3h) FEV1 at baseline and at all subsequent visits, and the respective changes from baseline are presented by treatment group for all clinical visits. Baseline for pre-dose FEV1 was calculated as average of the FEV1 measurements (L) from the visit 2 (V2) Pre45min \& V2 Pre15min. If one of the two pre-dose values was missing, the baseline was equal to the available pre-dose value. FEV1=Forced expiratory volume in the first second

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Least squares mean · Liter
6_Change From Baseline in Peak FEV1 (0-3h) at All Clinical Visits
LiterCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
Week 00.465 (0.438 to 0.492)0.407 (0.380 to 0.434)0.467 (0.429 to 0.505)
Week 40.533 (0.501 to 0.564)0.439 (0.408 to 0.471)0.559 (0.515 to 0.604)
Week 120.528 (0.495 to 0.561)0.433 (0.400 to 0.466)0.545 (0.499 to 0.591)
Week 260.522 (0.488 to 0.556)0.417 (0.383 to 0.451)0.555 (0.507 to 0.603)
Week 400.522 (0.488 to 0.556)0.414 (0.380 to 0.448)0.520 (0.472 to 0.568)
Week 520.501 (0.467 to 0.535)0.410 (0.375 to 0.444)0.529 (0.481 to 0.578)
Statistical analysis
  • CHF 5993 200/6/12.5 µg · Linear Mixed Model for Repeated Measures · p = 0.003 · Adjusted mean difference: 0.058 · 95% CI 0.020 to 0.097
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.945 · Adjusted mean difference: -0.002 · 95% CI -0.048 to 0.045
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.093 · 95% CI 0.048 to 0.138
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.333 · Adjusted mean difference: -0.027 · 95% CI -0.081 to 0.028
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.095 · 95% CI 0.048 to 0.141
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.551 · Adjusted mean difference: -0.017 · 95% CI -0.074 to 0.040
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.105 · 95% CI 0.057 to 0.153
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.271 · Adjusted mean difference: -0.033 · 95% CI -0.092 to 0.026
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.108 · 95% CI 0.060 to 0.157
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.943 · Adjusted mean difference: 0.002 · 95% CI -0.057 to 0.061
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.091 · 95% CI 0.043 to 0.140
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.348 · Adjusted mean difference: -0.028 · 95% CI -0.087 to 0.031
Secondary7_Change From Baseline in Pre-Dose FEV1 at All Clinical Visits

Results show the change from baseline in pre-dose FEV1 at all clinical visits. FEV1=Forced expiratory volume in the first second

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Least squares mean · Liter
7_Change From Baseline in Pre-Dose FEV1 at All Clinical Visits
LiterCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
Week 40.218 (0.189 to 0.248)0.149 (0.119 to 0.179)0.254 (0.212 to 0.296)
Week 120.241 (0.210 to 0.272)0.162 (0.131 to 0.194)0.250 (0.206 to 0.294)
Week 260.229 (0.196 to 0.263)0.157 (0.123 to 0.190)0.274 (0.227 to 0.321)
Week 400.255 (0.221 to 0.290)0.162 (0.128 to 0.196)0.250 (0.201 to 0.298)
Week 520.238 (0.205 to 0.272)0.152 (0.118 to 0.186)0.267 (0.219 to 0.314)
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.001 · Adjusted mean difference: 0.069 · 95% CI 0.027 to 0.111
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.175 · Adjusted mean difference: -0.036 · 95% CI -0.087 to 0.016
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.079 · 95% CI 0.035 to 0.123
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.749 · Adjusted mean difference: -0.009 · 95% CI -0.063 to 0.045
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.003 · Adjusted mean difference: 0.073 · 95% CI 0.026 to 0.120
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.125 · Adjusted mean difference: -0.045 · 95% CI -0.103 to 0.013
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.093 · 95% CI 0.045 to 0.142
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.849 · Adjusted mean difference: 0.006 · 95% CI -0.053 to 0.065
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.086 · 95% CI 0.038 to 0.134
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.347 · Adjusted mean difference: -0.028 · 95% CI -0.087 to 0.030
Secondary8_FEV1 Response (FEV1 ≥ 100 mL) at Week 26 and Week 52

Results show the percentage of patients classified as FEV1 responders at Week 26 and at Week 52. The FEV1 response was defined as: Change from baseline in pre-dose morning FEV1 ≥ 100 mL. FEV1=Forced expiratory volume in the first second

Time frame:
Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
Reported as:
Count of participants · Participants
8_FEV1 Response (FEV1 ≥ 100 mL) at Week 26 and Week 52
ParticipantsCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg
Week 26328257174
Week 52326241158
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Logistic model · p = < 0.001 · Odds ratio (or): 1.660 · 95% CI 1.312 to 2.099
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Logistic model · p = 0.381 · Odds ratio (or): 0.878 · 95% CI 0.657 to 1.174
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Logistic model · p = < 0.001 · Odds ratio (or): 1.831 · 95% CI 1.447 to 2.317
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Logistic model · p = 0.562 · Odds ratio (or): 1.088 · 95% CI 0.817 to 1.449
Secondary9_Change From Baseline in FEV1 Area Under the Curve (AUC) (0-3h) Normalised by Time at All Clinical Visits

Baseline definition: mean of two pre-dose FEV1 measurements at visit 2 (V2). Results show the change from baseline in FEV1 area under the curve \[AUC\] (0-3h) at all subsequent visits (i.e. change from baseline of the AUC of the serial post-dose spirometry assessments till 3h post-dose). FEV1=Forced expiratory volume in the first second

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Least squares mean · Liter
9_Change From Baseline in FEV1 Area Under the Curve (AUC) (0-3h) Normalised by Time at All Clinical Visits
LiterCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
Week 00.357 (0.333 to 0.382)0.309 (0.285 to 0.334)0.358 (0.324 to 0.393)
Week 40.443 (0.413 to 0.474)0.352 (0.322 to 0.383)0.472 (0.429 to 0.515)
Week 120.440 (0.409 to 0.472)0.343 (0.312 to 0.375)0.454 (0.409 to 0.499)
Week 260.429 (0.396 to 0.462)0.331 (0.298 to 0.365)0.465 (0.419 to 0.512)
Week 400.438 (0.404 to 0.471)0.328 (0.295 to 0.362)0.431 (0.383 to 0.478)
Week 520.416 (0.383 to 0.449)0.328 (0.294 to 0.361)0.442 (0.395 to 0.489)
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.006 · Adjusted mean difference: 0.048 · 95% CI 0.014 to 0.083
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.968 · Adjusted mean difference: -0.001 · 95% CI -0.043 to 0.041
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.091 · 95% CI 0.048 to 0.134
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.280 · Adjusted mean difference: -0.029 · 95% CI -0.082 to 0.024
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.097 · 95% CI 0.052 to 0.142
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.628 · Adjusted mean difference: -0.014 · 95% CI -0.068 to 0.041
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.098 · 95% CI 0.051 to 0.145
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.216 · Adjusted mean difference: -0.036 · 95% CI -0.093 to 0.021
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.109 · 95% CI 0.062 to 0.157
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.822 · Adjusted mean difference: 0.007 · 95% CI -0.052 to 0.065
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.088 · 95% CI 0.041 to 0.135
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.382 · Adjusted mean difference: -0.026 · 95% CI -0.084 to 0.032
Secondary10_Change From Baseline in the Asthma Control Questionnaire-7 (ACQ-7) Score at All Clinical Visits

ACQ-7 Questionnaire. ACQ-7 allows assessment of asthma control in individual patients. The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue medication use and 1 on lung function (FEV1 % predicted). All seven items are scored on a 7-point Likert scale, with 0 indicating total control (no impairment) and 6 indicating poor control (maximum impairment). The questions are equally weighted and the total score is the mean of the seven items. The first 6 questions of the ACQ-7 were completed by the participant while the last question was completed by the study investigator using data from the Master Scope spirometer. Baseline for ACQ-7 was the total score recorded at Visit 2 (Week 0) of the study. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. A negative change from baseline indicates improvement in lung function.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Least squares mean · score on a scale
10_Change From Baseline in the Asthma Control Questionnaire-7 (ACQ-7) Score at All Clinical Visits
score on a scaleCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
Week 4-0.573 (-0.621 to -0.524)-0.513 (-0.562 to -0.464)-0.576 (-0.645 to -0.507)
Week 12-0.699 (-0.752 to -0.646)-0.608 (-0.661 to -0.555)-0.704 (-0.779 to -0.630)
Week 26-0.766 (-0.823 to -0.710)-0.683 (-0.739 to -0.626)-0.766 (-0.845 to -0.686)
Week 40-0.796 (-0.854 to -0.738)-0.698 (-0.756 to -0.640)-0.767 (-0.849 to -0.684)
Week 52-0.842 (-0.902 to -0.783)-0.713 (-0.773 to -0.653)-0.772 (-0.857 to -0.688)
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.089 · Adjusted mean difference: -0.060 · 95% CI -0.129 to 0.009
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.933 · Adjusted mean difference: 0.004 · 95% CI -0.081 to 0.088
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.017 · Adjusted mean difference: -0.091 · 95% CI -0.166 to -0.016
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.911 · Adjusted mean difference: 0.005 · 95% CI -0.086 to 0.097
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.041 · Adjusted mean difference: -0.083 · 95% CI -0.163 to -0.003
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.990 · Adjusted mean difference: -0.001 · 95% CI -0.098 to 0.097
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.019 · Adjusted mean difference: -0.098 · 95% CI -0.181 to -0.016
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.563 · Adjusted mean difference: -0.030 · 95% CI -0.130 to 0.071
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.003 · Adjusted mean difference: -0.129 · 95% CI -0.213 to -0.045
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.184 · Adjusted mean difference: -0.070 · 95% CI -0.173 to 0.033
Secondary11_Asthma Control Questionnaire©-7 Response at Week 26 and Week 52

Asthma Control Questionnaire (ACQ) and Asthma Control Questionnaire-7 (QAC-7) are defined in the description of Outcome measure 10 above. An ACQ-7 response was defined as change from baseline (Week 0, pre-dose) in ACQ-7 score ≤ -0.5; non-response was defined as change from baseline in ACQ-7 score \>-0.5 or missing data. Results represent responders (i.e. change from baseline in ACQ-7 Score ≤ -0.5) at Week 26 and at Week 52.

Time frame:
Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
Reported as:
Count of participants · Participants
11_Asthma Control Questionnaire©-7 Response at Week 26 and Week 52
ParticipantsCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg
Week 26350319180
Week 52356332168
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Logistic model · p = 0.088 · Odds ratio (or): 1.233 · 95% CI 0.969 to 1.568
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Logistic model · p = 0.548 · Odds ratio (or): 0.913 · 95% CI 0.678 to 1.229
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Logistic model · p = 0.226 · Odds ratio (or): 1.161 · 95% CI 0.912 to 1.478
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Logistic model · p = 0.396 · Odds ratio (or): 1.136 · 95% CI 0.846 to 1.525
Secondary12_Change From Baseline in Average Morning PEF (L/Min) Over 52 Weeks of Treatment

Change from baseline in average MORNING PEF (L/min) over 52 weeks of treatment. PEF=Peak Expiratory Flow; is the maximal airflow forcefully expelled from the lungs in one quick exhalation.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Least squares mean · Liter/min
12_Change From Baseline in Average Morning PEF (L/Min) Over 52 Weeks of Treatment
Liter/minCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg
12_Change From Baseline in Average Morning PEF (L/Min) Over 52 Weeks of Treatment9.805 (6.159 to 13.450)1.563 (-2.087 to 5.214)8.055 (2.937 to 13.172)
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.002 · Adjusted mean difference: 8.242 · 95% CI 3.082 to 13.401
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.585 · Adjusted mean difference: 1.750 · 95% CI -4.533 to 8.033
Secondary12a_Change From Baseline in Average Evening PEF (L/Min) Over 26 and 52 Weeks of Treatment

Change from baseline in average EVENING PEF (L/min) over 26 and 52 weeks of treatment. PEF=Peak Expiratory Flow; is the maximal airflow forcefully expelled from the lungs in one quick exhalation.

Time frame:
Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
Reported as:
Least squares mean · Liter/min
12a_Change From Baseline in Average Evening PEF (L/Min) Over 26 and 52 Weeks of Treatment
Liter/minCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg
Weeks 1-268.965 (5.530 to 12.400)-0.306 (-3.744 to 3.131)14.249 (9.428 to 19.071)
Weeks 1-527.956 (4.276 to 11.636)-1.686 (-5.369 to 1.998)11.167 (5.999 to 16.336)
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 9.271 · 95% CI 4.411 to 14.131
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.080 · Adjusted mean difference: -5.285 · 95% CI -11.205 to 0.635
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 9.642 · 95% CI 4.434 to 14.849
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.321 · Adjusted mean difference: -3.211 · 95% CI -9.556 to 3.133
Secondary13_Number of Patients at Risk of Moderate or Severe Asthma Exacerbation Over 52 Weeks

Number of patients at risk of a moderate or severe asthma exacerbation. Results show the number of patients who had moderate or severe asthma exacerbation over the 52 weeks treatment period.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Count of participants · Participants
13_Number of Patients at Risk of Moderate or Severe Asthma Exacerbation Over 52 Weeks
ParticipantsCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg
13_Number of Patients at Risk of Moderate or Severe Asthma Exacerbation Over 52 Weeks323364162
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Cox proportional hazards analysis · p = 0.003 · Hazard ratio (hr): 0.799 · 95% CI 0.688 to 0.929
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Cox proportional hazards analysis · p = 0.777 · Hazard ratio (hr): 0.973 · 95% CI 0.805 to 1.175
  • CHF 1535 200/6 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Cox proportional hazards analysis · p = 0.038 · Hazard ratio (hr): 0.822 · 95% CI 0.683 to 0.989
Secondary14_Number of Patients at Risk of Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02

Number of patients at risk of a SEVERE asthma exacerbation in the pooled analysis of the two pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER), over the 52 weeks treatment period. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

Time frame:
Week 0 (Baseline) to 52 weeks for both studies in the pooled analysis.
Reported as:
Count of participants · Participants
14_Number of Patients at Risk of Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02
ParticipantsCHF 5993 200/6/12.5 µgCHF 1535 200/6 µg
14_Number of Patients at Risk of Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02209257
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Cox proportional hazards analysis · p = 0.011 · Hazard ratio (hr): 0.788 · 95% CI 0.656 to 0.946
Secondary15_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02.

MODERATE asthma exacerbation rate over the 52-Week treatment period in the pooled analysis of the 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-055993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

Time frame:
Week 0 (Baseline) to 52 weeks for both studies in the pooled analysis.
Reported as:
Least squares mean · events/year
15_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02.
events/yearCHF 5993 200/6/12.5 µgCHF 1535 200/6 µg
15_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02.1.515 (1.390 to 1.651)1.717 (1.577 to 1.869)
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Negative binomial model · p = 0.043 · Adjusted rate ratio: 0.883 · 95% CI 0.782 to 0.996
Secondary16_Number of Patients at Risk of MODERATE Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02

Number of Patients at Risk of MODERATE Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

Time frame:
Week 0 (Baseline) to 52 weeks for both studies in the pooled analysis.
Reported as:
Count of participants · Participants
16_Number of Patients at Risk of MODERATE Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02
ParticipantsCHF 5993 200/6/12.5 µgCHF 1535 200/6 µg
16_Number of Patients at Risk of MODERATE Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02588663
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Cox proportional hazards analysis · p = 0.001 · Hazard ratio (hr): 0.830 · 95% CI 0.743 to 0.927
Secondary17_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02

Moderate AND severe asthma exacerbation rate over the 52-Week treatment period in the pooled analysis of the 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

Time frame:
Week 0 (Baseline) to 52 weeks for both studies in the pooled analysis.
Reported as:
Least squares mean · events/year
17_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02
events/yearCHF 5993 200/6/12.5 µgCHF 1535 200/6 µg
17_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-021.788 (1.653 to 1.935)2.074 (1.920 to 2.241)
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Negative binomial model · p = 0.008 · Adjusted rate ratio: 0.862 · 95% CI 0.772 to 0.963
Secondary18_Number of Patients at Risk of Moderate OR Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02

Time to first MODERATE OR SEVERE asthma exacerbation in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

Time frame:
Week 0 (Baseline) to 52 weeks for both studies in the pooled analysis.
Reported as:
Count of participants · Participants
18_Number of Patients at Risk of Moderate OR Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02
ParticipantsCHF 5993 200/6/12.5 µgCHF 1535 200/6 µg
18_Number of Patients at Risk of Moderate OR Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02660743
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Cox proportional hazards analysis · p = <0.001 · Hazard ratio (hr): 0.820 · 95% CI 0.739 to 0.911
Secondary19_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period

MODERATE asthma exacerbation rate over the 52-Week treatment period. Asthma exacerbation intensity: Moderate: ≥1 of the following criteria fulfilled and leading to a change in treatment (sustained increase of ≥1 puff of short acting beta 2-agonist \[SABA\] for 2 consecutive days) as shown below: * Nocturnal awakening(s) due to asthma requiring SABA for 2 consecutive nights/increase of ≥ 0.75 from baseline in daily symptom score on 2 consecutive days; increase from baseline in occasions of SABA use on 2 consecutive days (minimum increase 4 puffs/day); * ≥20% decrease in peak expiratory flow from baseline on at least 2 consecutive mornings/evenings or ≥ 20% decrease in FEV1 from baseline; * Visit to the ER/trial site for asthma treatment not requiring systemic corticosteroid;

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Least squares mean · events/year
19_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period
events/yearCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg
19_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period1.430 (1.264 to 1.618)1.583 (1.401 to 1.788)1.366 (1.144 to 1.631)
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Negative binomial model · p = 0.250 · Adjusted rate ratio: 0.903 · 95% CI 0.760 to 1.074
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Negative binomial model · p = 0.680 · Adjusted rate ratio: 1.047 · 95% CI 0.843 to 1.300
Secondary20_Number of Patients at Risk of a MODERATE Asthma Exacerbation

Data were analysed for the number of patients at risk of a MODERATE asthma exacerbation.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Count of participants · Participants
20_Number of Patients at Risk of a MODERATE Asthma Exacerbation
ParticipantsCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg
20_Number of Patients at Risk of a MODERATE Asthma Exacerbation283320150
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Cox proportional hazards analysis · p = 0.009 · Hazard ratio (hr): 0.808 · 95% CI 0.688 to 0.948
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Cox proportional hazards analysis · p = 0.266 · Hazard ratio (hr): 0.894 · 95% CI 0.733 to 1.090
  • CHF 1535 200/6 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Cox proportional hazards analysis · p = 0.306 · Hazard ratio (hr): 0.904 · 95% CI 0.744 to 1.097
Secondary21_Change From Baseline in the Average Use of Rescue Medication Over the 26- and 52-Week Treatment Periods

Change from baseline in the average use of rescue medication over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study.

Time frame:
Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
Reported as:
Least squares mean · puffs/day
21_Change From Baseline in the Average Use of Rescue Medication Over the 26- and 52-Week Treatment Periods
puffs/dayCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg
Weeks 1-26-0.575 (-0.647 to -0.502)-0.550 (-0.623 to -0.478)-0.672 (-0.775 to -0.570)
Weeks 1-52-0.638 (-0.713 to -0.562)-0.582 (-0.658 to -0.506)-0.686 (-0.792 to -0.579)
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.640 · Adjusted mean difference: -0.024 · 95% CI -0.127 to 0.078
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.126 · Adjusted mean difference: 0.098 · 95% CI -0.028 to 0.223
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.304 · Adjusted mean difference: -0.056 · 95% CI -0.163 to 0.051
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.474 · Adjusted mean difference: 0.048 · 95% CI -0.083 to 0.179
Secondary21a_Change From Baseline in the Average Use of Rescue Medication in Each Inter-Visit Period

Results show the change from baseline in the average use (puffs/day) of rescue medication in each inter-visit period. Data was collected through an electronic daily diary from screening to the end of the study.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Mean · puffs/day
21a_Change From Baseline in the Average Use of Rescue Medication in Each Inter-Visit Period
puffs/dayCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg
Visit 2 - Visit 3 Weeks 1-4-0.409 ± 0.984-0.421 ± 1.005-0.543 ± 0.966
Visit 3 - Visit 4 Weeks 5-12-0.549 ± 1.089-0.559 ± 1.191-0.654 ± 1.143
Visit 4 - Visit 5 Weeks 13-26-0.636 ± 1.178-0.608 ± 1.279-0.738 ± 1.317
Visit 5 - Visit 6 Weeks 27-40-0.680 ± 1.236-0.624 ± 1.371-0.734 ± 1.357
Visit 6 - Visit 7 Weeks 41-52-0.726 ± 1.301-0.618 ± 1.350-0.706 ± 1.420
Secondary22_Change From Baseline in the Percentage of Rescue Medication-Free Days Over the 26- and 52-Week Treatment Periods

Change from baseline in the percentage of rescue medication-free days over the 26- and 52-Week treatment periods. Data was collected using an electronic daily diary, from screening to the end of the study.

Time frame:
Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
Reported as:
Least squares mean · percentage of days
22_Change From Baseline in the Percentage of Rescue Medication-Free Days Over the 26- and 52-Week Treatment Periods
percentage of daysCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg
Weeks 1-2615.786 (13.674 to 17.898)14.570 (12.453 to 16.687)18.390 (15.407 to 21.373)
Weeks 1-5217.566 (15.343 to 19.788)15.457 (13.229 to 17.685)19.740 (16.598 to 22.882)
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.425 · Adjusted mean difference: 1.216 · 95% CI -1.775 to 4.206
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.163 · Adjusted mean difference: -2.604 · 95% CI -6.260 to 1.052
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.189 · Adjusted mean difference: 2.109 · 95% CI -1.039 to 5.256
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.268 · Adjusted mean difference: -2.174 · 95% CI -6.024 to 1.675
Secondary22a_Change From Baseline in the Percentage of Rescue Medication-Free Days in Each Inter-Visit Period Over the Treatment

Results show the change from baseline in the percentage of rescue medication-free days in each inter-visit period over the entire treatment. Data was collected through an electronic daily diary from screening to the end of the study.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Mean · percentage of days
22a_Change From Baseline in the Percentage of Rescue Medication-Free Days in Each Inter-Visit Period Over the Treatment
percentage of daysCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg
Visit 2 - Visit 3 Weeks 1-410.075 ± 25.25111.380 ± 26.74014.435 ± 23.979
Visit 3 - Visit 4 Weeks 5-1214.196 ± 29.97114.668 ± 31.94517.854 ± 30.452
Visit 4 - Visit 5 Weeks 13-2617.297 ± 32.99016.094 ± 34.86721.453 ± 34.148
Visit 5 - Visit 6 Weeks 27-4018.216 ± 35.85716.600 ± 37.35222.261 ± 36.189
Visit 6 - Visit 7 Weeks 41-5219.603 ± 36.12916.942 ± 38.74922.541 ± 37.955
Secondary23_Change From Baseline in the Average Total Daily Asthma Symptom Scores Over the 26- and 52-Week Treatment Periods

Results show the change from baseline in the average total daily asthma symptom scores over the 26- and 52-Weeks of treatment. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered: cough, wheeze, chest tightness, breathlessness. Morning (night-time asthma symptom score): * 0 No symptoms; * 1 Mild = Symptoms not causing awakening; * 2 Moderate = Discomfort enough to cause awakenings; * 3 Severe = Causing awakenings for most of the night/did not sleep at all. Evening (daytime asthma symptom score): * 0 No symptoms; * 1 Mild = Aware of symptoms, which could be easily tolerated; * 2 Moderate = Discomfort enough to cause interference with daily activity; * 3 Severe = Incapacitating

Time frame:
Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
Reported as:
Least squares mean · score on a scale
23_Change From Baseline in the Average Total Daily Asthma Symptom Scores Over the 26- and 52-Week Treatment Periods
score on a scaleCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg
Weeks 1-26-0.186 (-0.211 to -0.160)-0.175 (-0.201 to -0.149)-0.194 (-0.231 to -0.158)
Weeks 1-52-0.208 (-0.236 to -0.180)-0.191 (-0.219 to -0.163)-0.207 (-0.246 to -0.167)
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.564 · Adjusted mean difference: -0.011 · 95% CI -0.047 to 0.026
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.709 · Adjusted mean difference: 0.008 · 95% CI -0.036 to 0.053
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.383 · Adjusted mean difference: -0.018 · 95% CI -0.057 to 0.022
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.959 · Adjusted mean difference: -0.001 · 95% CI -0.050 to 0.047
Secondary23a_Change From Baseline in the Average Daily Asthma Symptom Scores in Each Inter-Visit Period

Results show the change from baseline in the average total daily asthma symptom scores over the 26- and 52-Weeks of treatment. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered: cough, wheeze, chest tightness, breathlessness. Morning (night-time asthma symptom score): * 0 No symptoms; * 1 Mild = Symptoms not causing awakening; * 2 Moderate = Discomfort enough to cause awakenings; * 3 Severe = Causing awakenings for most of the night/did not sleep at all. Evening (daytime asthma symptom score): * 0 No symptoms; * 1 Mild = Aware of symptoms, which could be easily tolerated; * 2 Moderate = Discomfort enough to cause interference with daily activity; * 3 Severe = Incapacitating

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Mean · score on a scale
23a_Change From Baseline in the Average Daily Asthma Symptom Scores in Each Inter-Visit Period
score on a scaleCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg
Visit 2 - Visit 3 Weeks 1-4-0.116 ± 0.288-0.121 ± 0.274-0.140 ± 0.291
Visit 3 - Visit 4 Weeks 5-12-0.174 ± 0.348-0.171 ± 0.355-0.183 ± 0.351
Visit 4 - Visit 5 Weeks 13-26-0.211 ± 0.393-0.199 ± 0.407-0.218 ± 0.381
Visit 5 - Visit 6 Weeks 27-40-0.228 ± 0.433-0.210 ± 0.440-0.237 ± 0.402
Visit 6 - Visit 7 Weeks 41-52-0.240 ± 0.437-0.209 ± 0.462-0.219 ± 0.441
Secondary24_Change From Baseline in the Percentage of Asthma Symptom-Free Days Over the 26- and 52-Week Treatment Periods

Change from baseline in the percentage of asthma symptom-free days over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study. Results show the change from baseline in the average daily asthma symptom scores over the 26- and 52-Week treatment periods. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered by the questionnaire: cough, wheeze, chest tightness, breathlessness. An asthma symptom-free day is a day with total daily asthma symptom score = 0. For a description of the score see outcome measure number 23.

Time frame:
Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
Reported as:
Least squares mean · percentage of days
24_Change From Baseline in the Percentage of Asthma Symptom-Free Days Over the 26- and 52-Week Treatment Periods
percentage of daysCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg
Weeks 1-2613.187 (11.150 to 15.224)10.358 (8.316 to 12.400)10.419 (7.541 to 13.296)
Weeks 1-5216.569 (14.298 to 18.840)12.790 (10.513 to 15.067)12.725 (9.514 to 15.937)
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.055 · Adjusted mean difference: 2.829 · 95% CI -0.056 to 5.713
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.124 · Adjusted mean difference: 2.768 · 95% CI -0.757 to 6.294
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.021 · Adjusted mean difference: 3.779 · 95% CI 0.563 to 6.995
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.055 · Adjusted mean difference: 3.843 · 95% CI -0.090 to 7.777
Secondary24a_Change From Baseline in the Percentage of Asthma Symptom-Free Days in Each Inter-Visit Periods

Results show the change from baseline in the percentage of asthma symptom-free days in each inter-visit periods over the entire treatment. Data was collected through an electronic daily diary from screening to end of the study. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered by the questionnaire: cough, wheeze, chest tightness, breathlessness. An asthma symptom-free day is a day with total daily asthma symptom score = 0. For a description of the score see outcome measure number 23.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Mean · percentage of days
24a_Change From Baseline in the Percentage of Asthma Symptom-Free Days in Each Inter-Visit Periods
percentage of daysCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg
Visit 2 - Visit 3 Weeks 1-46.260 ± 19.5325.316 ± 19.1544.921 ± 16.053
Visit 3 - Visit 4 Weeks 5-1211.267 ± 26.7929.319 ± 25.4309.663 ± 24.046
Visit 4 - Visit 5 Weeks 13-2616.053 ± 31.19912.839 ± 30.23512.328 ± 27.339
Visit 5 - Visit 6 Weeks 27-4019.543 ± 34.70514.891 ± 32.35514.663 ± 31.889
Visit 6 - Visit 7 Weeks 41-5220.661 ± 35.94915.737 ± 33.93115.949 ± 33.004
Secondary25_Change From Baseline in the Percentage of Asthma Control Days Over the 26- and 52-Week Treatment Periods

Results show the change from baseline in the percentage of asthma control days over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study. Scoring of asthma symptoms (overall symptoms, cough, wheeze, chest tightness and breathlessness): Morning (night-time asthma symptoms): 0 (no symptoms), 1 (mild - symptoms not causing awakening), 2 (moderate - discomfort enough to cause awakenings) and 3 (severe - causing awakenings for most of the night/did not sleep at all). Evening (daytime asthma symptoms): 0 (no symptoms), 1 (mild: aware of symptoms that could be easily tolerated), 2 (moderate: discomfort enough to cause interference with daily activity), 3 (severe: incapacitating with inability to work/take part in usual activity).

Time frame:
Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
Reported as:
Least squares mean · percentage of days
25_Change From Baseline in the Percentage of Asthma Control Days Over the 26- and 52-Week Treatment Periods
percentage of daysCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg
Weeks 1-2612.469 (10.482 to 14.457)9.950 (7.958 to 11.942)10.356 (7.548 to 13.164)
Weeks 1-5215.601 (13.389 to 17.813)12.088 (9.870 to 14.307)12.530 (9.401 to 15.658)
Statistical analysis
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.079 · Adjusted mean difference: 2.519 · 95% CI -0.295 to 5.334
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg · Linear Mixed Model for Repeated Measures · p = 0.228 · Adjusted mean difference: 2.113 · 95% CI -1.327 to 5.553
  • CHF 5993 200/6/12.5 µg vs CHF 1535 200/6 µg · Linear Mixed Model for Repeated Measures · p = 0.028 · Adjusted mean difference: 3.513 · 95% CI 0.379 to 6.646
  • CHF 5993 200/6/12.5 µg · Linear Mixed Model for Repeated Measures · p = 0.116 · Adjusted mean difference: 3.071 · 95% CI -0.760 to 6.903
Secondary25a_Change From Baseline in the Percentage of Asthma Control Days in Each Inter-Visit Period

A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Data was collected through an electronic daily diary from screening to the end of the study. Scoring of asthma symptoms (overall symptoms, cough, wheeze, chest tightness and breathlessness): Morning (night-time asthma symptoms): 0 (no symptoms), 1 (mild - symptoms not causing awakening), 2 (moderate - discomfort enough to cause awakenings) and 3 (severe - causing awakenings for most of the night/did not sleep at all). Evening (daytime asthma symptoms): 0 (no symptoms), 1 (mild: aware of symptoms that could be easily tolerated), 2 (moderate: discomfort enough to cause interference with daily activity), 3 (severe: incapacitating with inability to work/ take part in usual activity).

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Mean · percentage of days
25a_Change From Baseline in the Percentage of Asthma Control Days in Each Inter-Visit Period
percentage of daysCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg
Visit 2 - Visit 3 Weeks 1-46.014 ± 18.9185.348 ± 18.4935.078 ± 15.955
Visit 3 - Visit 4 Weeks 5-1210.666 ± 26.1479.138 ± 24.5419.659 ± 24.071
Visit 4 - Visit 5 Weeks 13-2615.062 ± 30.33212.180 ± 29.13312.214 ± 27.180
Visit 5 - Visit 6 Weeks 27-4018.221 ± 33.55714.035 ± 31.70414.295 ± 31.514
Visit 6 - Visit 7 Weeks 41-5219.383 ± 34.48214.619 ± 33.16615.731 ± 32.685

Adverse events

Collected over Adverse events (AE) were reported from the time of patient informed consent signature until study completion week 52 or study discontinuation.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CHF 5993 200/6/12.5 µg1/571 (0.2%)28/571 (4.9%)406/571 (71.1%)
CHF 1535 200/6 µg1/573 (0.2%)33/573 (5.8%)437/573 (76.3%)
CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg0/287 (0%)15/287 (5.2%)207/287 (72.1%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
AsthmaRespiratory, thoracic and mediastinal disorders11/57111/5736/287
PneumoniaInfections and infestations3/5715/5732/287
Cardiac hypertrophyCardiac disorders0/5710/5731/287
GastritisGastrointestinal disorders0/5710/5731/287
PancreatitisGastrointestinal disorders0/5710/5731/287
AppendicitisInfections and infestations0/5710/5731/287
Perirectal abscessInfections and infestations0/5710/5731/287
Radius fractureInjury, poisoning and procedural complications0/5710/5731/287
Back disorderMusculoskeletal and connective tissue disorders0/5710/5731/287
GynaecomastiaReproductive system and breast disorders0/5710/5731/287
Most frequent other events
Showing 10 of 12
Most frequent other events
EventCHF 5993 200/6/12.5 µgCHF 1535 200/6 µgCHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
AsthmaRespiratory, thoracic and mediastinal disorders320/571361/573159/287
NasopharyngitisInfections and infestations46/57163/57334/287
Respiratory tract infection viralRespiratory, thoracic and mediastinal disorders17/57128/57314/287
HeadacheNervous system disorders25/57127/57313/287
BronchitisRespiratory, thoracic and mediastinal disorders18/57118/57312/287
Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders8/57115/5737/287
HypertensionVascular disorders10/5716/5737/287
Back painMusculoskeletal and connective tissue disorders12/5715/5737/287
PharyngitisRespiratory, thoracic and mediastinal disorders10/57112/5734/287
RhinitisRespiratory, thoracic and mediastinal disorders7/57112/5734/287

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CHF 5993CHF 1535CHF 1535 + Tiotropium (Tio)Total
<=18 years0000
Between 18 and 65 years4734502461169
>=65 years9812341262
Age, Continuous
Age, Continuous(years)CHF 5993CHF 1535CHF 1535 + Tiotropium (Tio)Total
Mean53.1 ± 12.254.0 ± 11.951.6 ± 12.353.2 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)CHF 5993CHF 1535CHF 1535 + Tiotropium (Tio)Total
Female359328184871
Male212245103560
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CHF 5993CHF 1535CHF 1535 + Tiotropium (Tio)Total
American Indian or Alaska Native0000
Asian2002
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White5695732861428
More than one race0000
Unknown or Not Reported0011
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)CHF 5993CHF 1535CHF 1535 + Tiotropium (Tio)Total
Mean28.36 ± 5.1428.67 ± 5.8728.46 ± 5.2128.50 ± 5.46
Duration of asthma disease
Duration of asthma disease(years)CHF 5993CHF 1535CHF 1535 + Tiotropium (Tio)Total
Mean24.8 ± 12.226.2 ± 12.624.5 ± 12.425.3 ± 12.4
Duration of asthma disease by group
Duration of asthma disease by group(Participants)CHF 5993CHF 1535CHF 1535 + Tiotropium (Tio)Total
< 5 years26211360
5-20 years18016596441
≥ 20 years365387178930
Number of asthma exacerbations in the previous year
Number of asthma exacerbations in the previous year(asthma exacerbations)CHF 5993CHF 1535CHF 1535 + Tiotropium (Tio)Total
Mean1.2 ± 0.41.2 ± 0.41.2 ± 0.41.2 ± 0.4

6 further baseline measures are reported on the registry.

08

Study locations

244 sites
  • Chiesi Clinical Trial Site 432702
    Buenos Aires, Argentina
  • Chiesi Clinical Trial Site 432704
    CABA, Argentina
  • Chiesi Clinical Trial Site 432705
    Mar del Plata, Argentina
  • Chiesi Clinical Trial Site 432701
    Quilmes, Argentina
  • Chiesi Clinical Trial Site 432703
    San Miguel de Tucumán, Argentina
  • Chiesi Clinical Trial Site 432706
    San Miguel de Tucumán, Argentina
  • Chiesi Clinical Trial Site 112703
    Homyel, Belarus
  • Chiesi Clinical Trial Site 112704
    Homyel, Belarus
  • Chiesi Clinical Trial Site 112701
    Minsk, Belarus
  • Chiesi Clinical Trial Site 112702
    Minsk, Belarus
  • Chiesi Clinical Trial Site 112705
    Minsk, Belarus
  • Chiesi Clinical Trial Site 100707
    Blagoevgrad, Bulgaria
  • Chiesi Clinical Trial Site 100720
    Burgas, Bulgaria
  • Chiesi Clinical Trial Site 100718
    Gabrovo, Bulgaria
  • Chiesi Clinical Trial Site 100713
    Haskovo, Bulgaria
  • Chiesi Clinical Trial Site 100722
    Montana, Bulgaria
  • Chiesi Clinical Trial Site 100702
    Pleven, Bulgaria
  • Chiesi Clinical Trial Site 100705
    Plovdiv, Bulgaria
  • Chiesi Clinical Trial Site 100708
    Plovdiv, Bulgaria
  • Chiesi Clinical Trial Site 100715
    Plovdiv, Bulgaria
  • Chiesi Clinical Trial Site 100716
    Rousse, Bulgaria
  • Chiesi Clinical Trial Site 100701
    Sofia, Bulgaria
  • Chiesi Clinical Trial Site 100703
    Sofia, Bulgaria
  • Chiesi Clinical Trial Site 100704
    Sofia, Bulgaria
  • Chiesi Clinical Trial Site 100709
    Sofia, Bulgaria
  • Chiesi Clinical Trial Site 100719
    Sofia, Bulgaria
  • Chiesi Clinical Trial Site 100706
    Stara Zagora, Bulgaria
  • Chiesi Clinical Trial Site 100712
    Stara Zagora, Bulgaria
  • Chiesi Clinical Trial Site 100710
    Varna, Bulgaria
  • Chiesi Clinical Trial Site 100711
    Vidin, Bulgaria
  • Chiesi Clinical Trial Site 100721
    Vidin, Bulgaria
  • Chiesi Clinical Trial Site 203711
    Blansko, Czechia
  • Chiesi Clinical Trial Site 203702
    Brandýs nad Labem, Czechia
  • Chiesi Clinical Trial Site 203708
    Brno, Czechia
  • Chiesi Clinical Trial Site 203707
    Jindřichův Hradec, Czechia
  • Chiesi Clinical Trial Site 203705
    Kralupy nad Vltavou, Czechia
  • Chiesi Clinical Trial Site 203709
    Miroslav, Czechia
  • Chiesi Clinical Trial Site 203704
    Opava, Czechia
  • Chiesi Clinical Trial Site 203701
    Prague, Czechia
  • Chiesi Clinical Trial Site 203703
    Prague, Czechia
  • Chiesi Clinical Trial Site 203710
    Prague, Czechia
  • Chiesi Clinical Trial Site 203713
    Rokycany, Czechia
  • Chiesi Clinical Trial Site 203706
    Teplice, Czechia
  • Chiesi Clinical Trial Site 203712
    Varnsdorf, Czechia
  • Chiesi Clinical Trial Site 276709
    Berlin, Germany
  • Chiesi Clinical Trial Site 276712
    Berlin, Germany
  • Chiesi Clinical Trial Site 276711
    Bonn, Germany
  • Chiesi Clinical Trial Site 276707
    Frankfurt am Main, Germany
  • Chiesi Clinical Trial Site 276714
    Frankfurt am Main, Germany
  • Chiesi Clinical Trial Site 276705
    Hamburg, Germany
  • Chiesi Clinical Trial Site 276703
    Hanover, Germany
  • Chiesi Clinical Trial Site 276708
    Koblenz, Germany
  • Chiesi Clinical Trial Site 276702
    Leipzig, Germany
  • Chiesi Clinical Trial Site 276704
    Leipzig, Germany
  • Chiesi Clinical Trial Site 276710
    Leipzig, Germany
  • Chiesi Clinical Trial Site 276715
    Mainz, Germany
  • Chiesi Clinical Trial Site 276701
    München, Germany
  • Chiesi Clinical Trial Site 276713
    Münster, Germany
  • Chiesi Clinical Trial Site 276716
    Rosenheim, Germany
  • Chiesi Clinical Trial Site 348707
    Balassagyarmat, Hungary
  • Chiesi Clinical Trial Site 348715
    Budapest, Hungary
  • Chiesi Clinical Trial Site 348721
    Debrecen, Hungary
  • Chiesi Clinical Trial Site 348708
    Érd, Hungary
  • Chiesi Clinical Trial Site 348712
    Gödöllő, Hungary
  • Chiesi Clinical Trial Site 348718
    Hatvan, Hungary
  • Chiesi Clinical Trial Site 348717
    Komárom, Hungary
  • Chiesi Clinical Trial Site 348709
    Létavértes, Hungary
  • Chiesi Clinical Trial Site 348703
    Monor, Hungary
  • Chiesi Clinical Trial Site 348719
    Mórahalom, Hungary
  • Chiesi Clinical Trial Site 348704
    Nyíregyháza, Hungary
  • Chiesi Clinical Trial Site 348714
    Nyíregyháza, Hungary
  • Chiesi Clinical Trial Site 348713
    Pécs, Hungary
  • Chiesi Clinical Trial Site 348720
    Pécs, Hungary
  • Chiesi Clinical Trial Site 348702
    Siófok, Hungary
  • Chiesi Clinical Trial Site 348706
    Szarvas, Hungary
  • Chiesi Clinical Trial Site 348701
    Szeged, Hungary
  • Chiesi Clinical Trial Site 348705
    Szombathely, Hungary
  • Chiesi Clinical Trial Site 348710
    Vásárosnamény, Hungary
  • Chiesi Clinical Trial Site 380704
    Bologna, Italy
  • Chiesi Clinical Trial Site 380703
    Catania, Italy
  • Chiesi Clinical Trial Site 380701
    Genova, Italy
  • Chiesi Clinical Trial Site 380705
    Palermo, Italy
  • Chiesi Clinical Trial Site 380702
    Pavia, Italy
  • Chiesi Clinical Trial Site 380706
    Tradate, Italy
  • Chiesi Clinical Trial Site 440701
    Šiauliai, Lithuania
  • Chiesi Clinical Trial Site 440702
    Vilnius, Lithuania
  • Chiesi Clinical Trial Site 440703
    Vilnius, Lithuania
  • Chiesi Clinical Trial Site 440705
    Vilnius, Lithuania
  • Chiesi Clinical Trial Site 616713
    Bialystok, Poland
  • Chiesi Clinical Trial Site 616718
    Bialystok, Poland
  • Chiesi Clinical Trial Site 616722
    Bielsko-Biala, Poland
  • Chiesi Clinical Trial Site 616702
    Bienkówka, Poland
  • Chiesi Clinical Trial Site 616727
    Bydgoszcz, Poland
  • Chiesi Clinical Trial Site 616704
    Giżycko, Poland
  • Chiesi Clinical Trial Site 616716
    Grudziądz, Poland
  • Chiesi Clinical Trial Site 616725
    Katowice, Poland
  • Chiesi Clinical Trial Site 616729
    Katowice, Poland
  • Chiesi Clinical Trial Site 616719
    Krakow, Poland
  • Chiesi Clinical Trial Site 616734
    Krakow, Poland
  • Chiesi Clinical Trial Site 616736
    Krakow, Poland

Showing the first 100 of 244 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Virchow JC, Kuna P, Paggiaro P, Papi A, Singh D, Corre S, Zuccaro F, Vele A, Kots M, Georges G, Petruzzelli S, Canonica GW. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019 Nov 9;394(10210):1737-1749. doi: 10.1016/S0140-6736(19)32215-9. Epub 2019 Sep 30. PubMed 31582314 ↗
  • Oba Y, Anwer S, Maduke T, Patel T, Dias S. Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2022 Dec 6;12(12):CD013799. doi: 10.1002/14651858.CD013799.pub2. PubMed 36472162 ↗
  • Orlovic M, Magni T, Lukyanov V, Guerra I, Madoni A. Cost-effectiveness of single-inhaler extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium in patients with uncontrolled asthma in England. Respir Med. 2022 Sep;201:106934. doi: 10.1016/j.rmed.2022.106934. Epub 2022 Jul 19. PubMed 35872377 ↗
  • Papi A, Singh D, Virchow JC, Canonica GW, Vele A, Georges G. Normalisation of airflow limitation in asthma: Post-hoc analyses of TRIMARAN and TRIGGER. Clin Transl Allergy. 2022 Apr 17;12(4):e12145. doi: 10.1002/clt2.12145. eCollection 2022 Apr. PubMed 35450196 ↗
  • Singh D, Virchow JC, Canonica GW, Vele A, Kots M, Georges G, Papi A. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER. Respir Res. 2020 Oct 29;21(1):285. doi: 10.1186/s12931-020-01558-y. PubMed 33121501 ↗
  • Singh D, Virchow JC, Canonica GW, Vele A, Kots M, Georges G, Papi A. Extrafine triple therapy in patients with asthma and persistent airflow limitation. Eur Respir J. 2020 Sep 24;56(3):2000476. doi: 10.1183/13993003.00476-2020. Print 2020 Sep. No abstract available. PubMed 32430414 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Chiesi commits to sharing with qualified scientific and medical researchers, conducting legitimate research, patient-level data, study-level data, the clinical protocol and the full CSR, providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared patient-level data is anonymized to protect personally identifiable information. Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.

Time frame: See information above in Plan Description regarding Chiesi's commitment to share information with qualified scientific and medical researchers, conducting legitimate research Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.

Access criteria: Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.

Data sharing details ↗ · www.chiesi.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in May 2018, 25 months.

Results were first posted in May 2026, 8 years after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 25 months is close to that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2016
First posted
Feb 8, 2016
StartActual
Apr 6, 2016
Primary completionActual
May 28, 2018
CompletionActual
May 28, 2018
Results first posted
May 29, 2026
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02676089
Responsible party
Sponsor
First posted
Feb 8, 2016
Start date
Apr 6, 2016
Primary completion
May 28, 2018
Completion
May 28, 2018
Results posted
May 29, 2026
Last update
Jun 26, 2026

Study contacts

Georgio Walter Canonica, MD
principal investigator · University of Medicine, Genoa, Italy

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion